Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial

BACKGROUND: A Tat Oyi vaccine preparation was administered with informed consent to 48 long-term HIV-1 infected volunteers whose viral loads had been suppressed by antiretroviral therapy (cART). These volunteers were randomized in double-blind method into four groups (n = 12) that were injected intr...

Descripción completa

Detalles Bibliográficos
Autores principales: Loret, Erwann P., Darque, Albert, Jouve, Elisabeth, Loret, Elvenn A., Nicolino-Brunet, Corinne, Morange, Sophie, Castanier, Elisabeth, Casanova, Josiane, Caloustian, Christine, Bornet, Charléric, Coussirou, Julie, Boussetta, Jihen, Couallier, Vincent, Blin, Olivier, Dussol, Bertrand, Ravaux, Isabelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818470/
https://www.ncbi.nlm.nih.gov/pubmed/27036656
http://dx.doi.org/10.1186/s12977-016-0251-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818470/
https://www.ncbi.nlm.nih.gov/pubmed/27036656
http://dx.doi.org/10.1186/s12977-016-0251-3

Ejemplares similares